Company: NDRA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001654954-25-003612
Chunk: 641

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 5
Chunk 641
---
          Liabilities and Stockholders’ Equity        Current Liabilities        Accounts payable and accrued liabilities $508,293  $700,754 Lease liabilities, current portion  96,937   173,857 Loans  -   28,484 Total Current Liabilities  605,230   903,095          Long Term Debt        Loans, long term  -   - Lease liabilities  487,482   192,062 Warrant Liability  799,284   - Total Long Term Debt  1,286,766   192,062          Total Liabilities  1,891,996   1,095,157          Stockholders’ Equity        Series A Convertible Preferred Stock, $0.0001 par value; 10,000 shares authorized; 17.488 and 141.397 shares issued and outstanding, respectively  -   1 Series B Convertible Preferred Stock, $0.0001 par value; 1,000 shares authorized; no shares issued and outstanding  -   - Series C Preferred Stock, $0.0001 par value; 100,000 shares authorized; no shares issued and outstanding  -   - Common stock, $0.0001 par value; 20,000,000 shares authorized; 536,908 and 5,937 shares issued and outstanding, respectively  53   1 Additional paid in capital  105,998,412   97,583,906 Stock payable  -   5,233 Accumulated deficit  (103,438,099)  (91,930,152)Total Stockholders’ Equity  2,560,366   5,658,989 Total Liabilities and Stockholders’ Equity $4,452,362  $6,754,146 

The accompanying notes are an integral part of these consolidated financial statements.

 F-2 

ENDRA Life Sciences Inc.

Consolidated Statements of Operations

  Year Ended  Year Ended   December 31,   December 31,    2024  2023 Operating Expenses      Research and development $3,190,293  $5,003,695 Sales and marketing  571,040